Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Non Operating Income: 2012-2025

Historic Non Operating Income for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $6.5 million.

  • Ptc Therapeutics' Non Operating Income rose 447.33% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 80.13%. This contributed to the annual value of $6.5 million for FY2024, which is 35.40% down from last year.
  • Ptc Therapeutics' Non Operating Income amounted to $6.5 million in Q3 2025, which was up 213.33% from -$5.7 million recorded in Q2 2025.
  • Ptc Therapeutics' Non Operating Income's 5-year high stood at $35.1 million during Q4 2022, with a 5-year trough of -$38.1 million in Q3 2022.
  • Moreover, its 3-year median value for Non Operating Income was $1.5 million (2023), whereas its average is $1.0 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Non Operating Income tumbled by 1,183.82% in 2022, and later spiked by 447.33% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Non Operating Income stood at -$31.4 million in 2021, then soared by 212.02% to $35.1 million in 2022, then crashed by 46.05% to $19.0 million in 2023, then plummeted by 53.33% to $8.8 million in 2024, then soared by 447.33% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, -$5.7 million for Q2 2025, and -$6.3 million during Q1 2025.